Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from BB Biotech ( (CH:BION) ).
BB Biotech AG has announced a change in shareholdings, with Saba Capital Management, L.P. from New York, USA, acquiring a stake that results in a total voting rights percentage below 3%. This disclosure reflects a shift in investor composition, potentially impacting the company’s market perception and stakeholder interests.
The most recent analyst rating on (CH:BION) stock is a Buy with a CHF66.00 price target. To see the full list of analyst forecasts on BB Biotech stock, see the CH:BION Stock Forecast page.
More about BB Biotech
BB Biotech AG operates in the biotechnology industry, focusing on investments in companies developing and marketing innovative drugs and therapies. The company is known for its strategic investments in the biotech sector, aiming to capitalize on the growth and advancements in medical treatments.
YTD Price Performance: -11.50%
Average Trading Volume: 100,615
Current Market Cap: CHF1.63B
See more insights into BION stock on TipRanks’ Stock Analysis page.